FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,501,768 | -57.6% | 2,595,174 | -4.9% | 0.00% | 0.0% |
| Q2 2023 | $12,988,340 | +32.0% | 2,728,643 | +58.1% | 0.00% | 0.0% |
| Q1 2023 | $9,837,000 | +66357.2% | 1,725,729 | +17.6% | 0.00% | -50.0% |
| Q4 2022 | $14,802 | -100.0% | 1,467,004 | -27.8% | 0.00% | -71.4% |
| Q3 2022 | $45,564,000 | -7.9% | 2,033,203 | +1.8% | 0.01% | 0.0% |
| Q2 2022 | $49,496,000 | -31.4% | 1,997,407 | +7.3% | 0.01% | -22.2% |
| Q1 2022 | $72,177,000 | -36.2% | 1,861,706 | -3.7% | 0.01% | -30.8% |
| Q4 2021 | $113,069,000 | +12.0% | 1,932,464 | +13.5% | 0.01% | +8.3% |
| Q3 2021 | $100,914,000 | -26.0% | 1,702,615 | +8.3% | 0.01% | -25.0% |
| Q2 2021 | $136,396,000 | +137.1% | 1,571,563 | +125.2% | 0.02% | +100.0% |
| Q1 2021 | $57,525,000 | +5.4% | 697,700 | +16.3% | 0.01% | 0.0% |
| Q4 2020 | $54,558,000 | +133.1% | 600,002 | +1.0% | 0.01% | +100.0% |
| Q3 2020 | $23,406,000 | +29.2% | 594,055 | +12.5% | 0.00% | +33.3% |
| Q2 2020 | $18,119,000 | +75.7% | 528,077 | +13.7% | 0.00% | +50.0% |
| Q1 2020 | $10,315,000 | +61.3% | 464,433 | +42.1% | 0.00% | +100.0% |
| Q4 2019 | $6,395,000 | +47.2% | 326,820 | +16.8% | 0.00% | 0.0% |
| Q3 2019 | $4,344,000 | -22.6% | 279,751 | +2.0% | 0.00% | 0.0% |
| Q2 2019 | $5,609,000 | +19.4% | 274,394 | +2.6% | 0.00% | 0.0% |
| Q1 2019 | $4,699,000 | -20.4% | 267,453 | -41.8% | 0.00% | 0.0% |
| Q4 2018 | $5,901,000 | -18.1% | 459,893 | +4.0% | 0.00% | 0.0% |
| Q3 2018 | $7,206,000 | +40.8% | 442,382 | -2.0% | 0.00% | 0.0% |
| Q2 2018 | $5,117,000 | +22.7% | 451,241 | +5.6% | 0.00% | 0.0% |
| Q1 2018 | $4,172,000 | +2257.1% | 427,420 | +1371.4% | 0.00% | – |
| Q4 2017 | $177,000 | +63.9% | 29,048 | +10.0% | 0.00% | – |
| Q3 2017 | $108,000 | +58.8% | 26,413 | +25.7% | 0.00% | – |
| Q2 2017 | $68,000 | +580.0% | 21,010 | +870.0% | 0.00% | – |
| Q1 2017 | $10,000 | -33.3% | 2,166 | -56.2% | 0.00% | – |
| Q3 2016 | $15,000 | – | 4,941 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |